Figure 5From: A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideMedian platelet counts during the extension period. Bars represent interquartile ranges. Broken horizontal line is at 50 × 109/L.Back to article page